• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

FDA approves VisionCare’s telescope implant for AMD

Article

The U.S. Food and Drug Administration approved VisionCare Ophthalmic Technologies’ implantable miniature telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older.

Saratoga, CA-The U.S. Food and Drug Administration approved VisionCare Ophthalmic Technologies’ implantable miniature telescope for use in patients living with bilateral end-stage age-related macular degeneration (AMD) who are age 65 or older. The telescope implant is the only FDA approved surgical device for end-stage AMD and is Medicare eligible.

Current views on genetic testing for AMD

According to the company, the telescope implant improves visual acuity and quality of life for suitable patients with AMD whose sight is permanently obstructed by a blind spot in their central vision, making it difficult or impossible to see faces, read, and perform everyday activities such as watching TV, preparing meals, and self-care.

“Despite all the great pharmacotherapy advances in AMD treatment, some patients will unfortunately progress to end-stage AMD where their straight ahead, central vision is permanently blocked,” said Dr. David Boyer, of Retina Vitreous Associates Medical Group, Beverly Hills, CA. “Once end-stage AMD patients have lost their central vision, cataract surgery will not provide them with as much benefit to their quality of life as the telescope implant.”

The telescope implant is not a cure for end-stage AMD. According to the company, possible side effects include decreased vision or vision impairing corneal swelling.

Related Videos
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Steven Ferrucci, OD, FAAO - AAOpt
Janis Winters, OD, FAAO
Justin Schweitzer and Nate Lighthizer discuss surgical interventions in glaucoma at AOA 2023.
Justin Schweitzer and Nate Lighthizer discuss surgical interventions in glaucoma at AOA 2023.
Dr. Mohammad Rafieetary
© 2024 MJH Life Sciences

All rights reserved.